Modern treatment options for mixed and aerobic vaginitis

Abstract

Mixed vaginitis is closely associated with an increased risk of pelvic inflammatory disease, reproductive failures, preterm births, postpartum infectious and inflammatory complications, and cervical neoplasiae. The article considers the main issues of diagnosis and treatment of the disease, mainly caused by the polyetiological nature of mixed vaginitis and relapse tendencies. Effective techniques of integrated approach and impact on all etiological agents of mixed vaginitis with a minimal effect on the normal vaginal microflora are presented. In the modern obstetrics-gynecology practice, preference is given to combination drugs intended for topical use, and a rational choice of the dosage form ensures maximum patient compliance and treatment efficiency. It is topical dosage forms that contribute to the rapid delivery of the active substance to the inflammation site and do not have systemic effects characteristic of oral dosage forms. A new domestic multicomponent drug to treat vaginitis and prevent its development has been provided a market authorization on the Russian market. Its action is ensured by combined effects of the components in its composition, such as metronidazole (500 mg), chloramphenicol (200 mg), natamycin (150 mg), hydrocortisone acetate (15 mg), due to which the drug provides a wide range of etiotropic and symptomatic effects. The article presents the results of comparative clinical studies on assessment of the efficacy, tolerability and safety of the drug in the treatment of vulvovaginitis of mixed etiology. The Russian studies showed that this combination provides a minimal risk of systemic effects and the most favourable safety and tolerability profile of therapy as compared to the oral dosage forms, which gives grounds to recommend it for use in the clinical obstetrics-gynecology practice.